Antipyretic and anti-inflammatory effects of inosine, an active component of Kangfuxin

作者全名：Zhang, Yue; Jia, Daqi; Wu, Yipeng; Xu, Yongqing

作者地址：[Zhang, Yue; Wu, Yipeng] Kunming Med Univ, Dept Cardiol, 1168,Chunrong West Rd,Yuhua St, Kunming 650500, Peoples R China; [Zhang, Yue; Wu, Yipeng; Xu, Yongqing] 920th Hosp Joint Logist Support Force Chinese Peop, Dept Orthopaed, 212 Daguan Rd, Kunming 650032, Peoples R China; [Jia, Daqi] Chongqing Med Univ, Affiliated Banan Hosp, Dept Pathol, Longzhouwan St, Chongqing 401320, Peoples R China

通信作者：Xu, YQ (通讯作者)，920th Hosp Joint Logist Support Force Chinese Peop, Dept Orthopaed, 212 Daguan Rd, Kunming 650032, Peoples R China.

来源：IMMUNOBIOLOGY

ESI学科分类：IMMUNOLOGY

WOS号：WOS:001244890300001

JCR分区：Q3

影响因子：2.5

年份：2024

卷号：229

期号：3

开始页：　

结束页：　

文献类型：Article

关键词：　

摘要：Kangfuxin has been widely recognized for its use in treating ulcerative conditions and mucositis, primarily due to its anti-inflammatory properties, which promote cell proliferation, granulation tissue growth, and angiogenesis. However, the exact mechanisms underlying these effects remain poorly understood. In this study, we employed high -throughput mass spectrometry to identify 11 compounds in Kangfuxin, including uracil, hypoxanthine, xanthine, inosine, glutamic acid, glycine, alanine, valine, isoleucine, leucine, and lysine. Notably, the antipyretic and anti-inflammatory properties of inosine, one of these compounds, have not been well characterized. To address this gap, we induced fever in vivo using lipopolysaccharide (LPS) and conducted various experiments, including the analysis of endogenous mediators, inflammatory factors, quantitative polymerase chain reaction (QPCR), Western blotting, and hematoxylin and eosin (HE) staining. Our findings indicate that inosine significantly reduces LPS-induced fever, inhibits the expression of inflammatory factors, and alleviates the inflammatory response. These results suggest that inosine may serve as a potential therapeutic target for inflammatory diseases.

基金机构：Yunnan Orthopedics and Sports Rehabilitation Clinical Medicine Research Center [202102AA310068]; Yunnan Provincial Clinical Orthopedic Trauma Medical Center [ZX20191001]

基金资助正文：This work was supported by Yunnan Orthopedics and Sports Rehabilitation Clinical Medicine Research Center (No. 202102AA310068) and Yunnan Provincial Clinical Orthopedic Trauma Medical Center (No. ZX20191001).